These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 21763295)

  • 1. B domain containing Tenascin-C: a new urine marker for surveillance of patients with urothelial carcinoma of the urinary bladder?
    Gecks T; Junker K; Franz M; Richter P; Walther M; Voigt A; Neri D; Kosmehl H; Wunderlich H; Kiehntopf M; Berndt A
    Clin Chim Acta; 2011 Oct; 412(21-22):1931-6. PubMed ID: 21763295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B and C domain containing tenascin-C: urinary markers for invasiveness of urothelial carcinoma of the urinary bladder?
    Richter P; Tost M; Franz M; Altendorf-Hofmann A; Junker K; Borsi L; Neri D; Kosmehl H; Wunderlich H; Berndt A
    J Cancer Res Clin Oncol; 2009 Oct; 135(10):1351-8. PubMed ID: 19326143
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urinary BTA-TRAK in the follow-up of superficial transitional-cell bladder carcinoma].
    Fernández Gómez JM; García Rodríguez J; Escaf Barmadah S; Raigoso P; Rodríguez Martínez JJ; Allende MT; Casasola Chamorro J; Rodríguez Faba O; Martín Benito JL; Regadera Sejas FJ
    Arch Esp Urol; 2002; 55(1):41-9. PubMed ID: 11957750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical value of combined detection with urinary bladder cancer antigen, hyaluronic acid and cytokeratin 20 in diagnosis of bladder cancer].
    Pu XY; Wang ZP; Chen YR; Wu YL; Wang HP; Wang XH
    Ai Zheng; 2008 Sep; 27(9):970-3. PubMed ID: 18799038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of urine tumor-associated trypsin inhibitor, CYFRA 21-1, and urinary bladder cancer antigen for detection of high-grade bladder carcinoma.
    Gkialas I; Papadopoulos G; Iordanidou L; Stathouros G; Tzavara C; Gregorakis A; Lykourinas M
    Urology; 2008 Nov; 72(5):1159-63. PubMed ID: 18514770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder.
    Bhagirath D; Abrol N; Khan R; Sharma M; Seth A; Sharma A
    Clin Chim Acta; 2012 Oct; 413(19-20):1641-6. PubMed ID: 22626996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
    Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
    Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
    J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of tenascin-C splicing domains in urothelial carcinomas of the urinary bladder.
    Berndt A; Anger K; Richter P; Borsi L; Brack S; Silacci M; Franz M; Wunderlich H; Gajda M; Zardi L; Neri D; Kosmehl H
    J Cancer Res Clin Oncol; 2006 Aug; 132(8):537-46. PubMed ID: 16788848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
    May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
    Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combinations of urine-based tumour markers in bladder cancer surveillance.
    Horstmann M; Patschan O; Hennenlotter J; Senger E; Feil G; Stenzl A
    Scand J Urol Nephrol; 2009; 43(6):461-6. PubMed ID: 19903092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
    Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
    BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a new quantitative point-of-care test platform for urine-based detection of bladder cancer.
    Ritter R; Hennenlotter J; Kühs U; Hofmann U; Aufderklamm S; Blutbacher P; Deja A; Hohneder A; Gerber V; Gakis G; Stenzl A; Schwentner C; Todenhöfer T
    Urol Oncol; 2014 Apr; 32(3):337-44. PubMed ID: 24332643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
    Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
    Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Usefulness of urinary nuclear matrix protein 22 (NMP22) as a marker for transitional cell carcinoma of the bladder.
    Menendez V; Filella X; Alcover JA; Molina R; Mallafre JM; Ballesta AM; Talbot-Wright R
    Anticancer Res; 2000; 20(2B):1169-72. PubMed ID: 10810416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Qualitative and quantitative assessment of urinary cytokeratin 8 and 18 fragments compared with voided urine cytology in diagnosis of bladder carcinoma.
    Hakenberg OW; Fuessel S; Richter K; Froehner M; Oehlschlaeger S; Rathert P; Meye A; Wirth MP
    Urology; 2004 Dec; 64(6):1121-6. PubMed ID: 15596183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-6/10 ratio as a prognostic marker of recurrence in patients with intermediate risk urothelial bladder carcinoma.
    Cai T; Mazzoli S; Meacci F; Tinacci G; Nesi G; Zini E; Bartoletti R
    J Urol; 2007 Nov; 178(5):1906-11;discussion 1911-2. PubMed ID: 17868727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of cytology, nuclear matrix protein 22 (NMP22) test, and urinary bladder cancer II (UBC II) test in early recurrent transitional cell carcinoma of the bladder.
    Kibar Y; Goktas S; Kilic S; Yaman H; Onguru O; Peker AF
    Ann Clin Lab Sci; 2006; 36(1):31-8. PubMed ID: 16501234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urine concentration of nuclear matrix protein 22 for diagnosis of transitional cell carcinoma of bladder.
    Jamshidian H; Kor K; Djalali M
    Urol J; 2008; 5(4):243-7. PubMed ID: 19101898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.